Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesDemyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.Systemic methotrexate therapy for psoriasis: past, present and future.Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.Implementing treatment goals for successful long-term management of psoriasis.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Current and emerging systemic treatment strategies for psoriasis.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.Biologic fatigue in psoriasis.Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.Biological therapies for psoriasis.Treating moderate to severe psoriasis - best use of biologics.The risk of deep fungal infections during biologic therapy for psoriasis.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship.Systemic methotrexate for the treatment of psoriasis.Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis.A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.A Review of Psoriasis, Therapies, and Suicide.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Immunotargeting in the management of psoriasis.Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.Serious infections among a large cohort of subjects with systemically treated psoriasis.
P2860
Q26764867-47DE9020-FC47-4FD4-8919-85EB6976DF42Q26781755-778147AF-6A7F-46DE-8CD9-C9DDA53BAD96Q26991673-66EC218C-210B-421E-8554-2C73B17F7E8DQ30251926-AE0932ED-340E-452A-80F9-FFC5F5E35C0EQ33625546-F68DC98E-15CA-49BB-B42F-6B9CAC699C6DQ33969217-D13620EF-A096-49DF-B277-CDD4BB99F53DQ34166896-C4F68E72-B0B1-43E0-AA4D-960EFD842AD1Q34294189-F9599880-516C-46E4-A324-01CB6ACF344FQ34356265-7B6214D6-88EB-49D9-ABCE-64122EE2513CQ36014642-238806F0-8F95-4AC4-95BB-746023A62E4EQ36321264-7DDB5EB0-87BD-44D3-934C-33D4BE6346B9Q36417100-69314DC7-4D15-43DA-A901-D58A8730556EQ36539788-F25BC469-5757-4E6A-9AEE-3C040A200B41Q37258726-BB17E2E2-320A-4668-8379-6F5139412D1AQ37987269-DE18E146-DBB6-4636-B194-D3950C684500Q38024281-5D47E31C-027C-48F9-A287-904C801FBCAFQ38039491-9C3CE56B-9BF9-4599-A574-943BEC0DCEE5Q38084325-9C294ED3-5960-4EF8-AA6E-690942D3236CQ38123192-F8EB9D51-8422-460E-A812-54E17BBC8659Q38137277-B2C57079-7D1D-4007-B44F-B741A8157604Q38153077-A055B4CB-ADD7-4F77-8943-5E7016816527Q38155648-85ED3AB3-CA0C-4586-9F2E-E5C2581C381BQ38174153-D4F0C834-E28E-4A0E-A2D2-7FACA7CABD67Q38219217-3D4BF431-5683-477A-9E26-CDC0E2C0648FQ38235809-CAC8E5AD-70D0-40CC-9063-4226E56B126AQ38375060-28043192-328E-4DE9-AF36-F8177055D57BQ38380882-9F4BD22F-28B3-451B-ADDE-13CF5506FFE0Q38488577-2978D056-8F26-450D-94BD-0C26180416E8Q38623340-AE5BE562-A87C-471C-9875-ADCAE3A044CBQ38662868-FAC4B506-233B-498B-B46F-26DFF7C529EAQ38812025-6445B975-2E71-4DC5-8B53-207B777FC9DAQ38840271-45913ECE-98F0-4306-AEA0-505BB812FB79Q38858335-3FCA29F3-939B-436F-BFF9-EA9C950A9A77Q38912240-D577E626-7E8C-409B-9C0A-036AE9AF1E4EQ39046392-BE44D271-11E1-4259-9A6D-BDCB6CB9CF88Q39601823-6FAE2539-B25D-45AF-BDDF-9F597A2725C3Q40209526-BC28DC52-78EB-4AD1-AC54-C171B3D57321Q40590985-F5EC2940-68EA-4A36-BA49-B21A0F28FA4BQ43645804-A3170E44-DFF9-4658-953C-E20458FB5ADBQ46731189-E240D305-EFFF-4875-9809-E0EBC3732E12
P2860
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@en
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@nl
type
label
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@en
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@nl
prefLabel
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@en
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@nl
P2093
P2860
P1476
Efficacy and safety of inflixi ...... , randomized trial (RESTORE1).
@en
P2093
H van Hoogstraten
J-P Ortonne
M Hoffmann
P2860
P304
P356
10.1111/J.1365-2133.2011.10615.X
P407
P577
2011-11-01T00:00:00Z